Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer We calculated smudge cell percentages (ratio of ...

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

Researchers of this new study found that treatment with venetoclax may be able to restore activation and proliferation of these cells, suggesting their plasticity can be leveraged for autologous ...

An international team of researchers published an article (“Identification of altered cell signaling pathways using proteomic profiling in stable and progressive chronic lymphocytic leukemia”) in the ...

The goal of CLL management is to maintain the best quality of life and treat only when patients become symptomatic from their disease. 7,8 Unlike other hematologic malignancies, CLL is a long-term, ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.